QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 9 March 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
- 9 March 2020Portfolio NewsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
- 4 March 2020Portfolio NewsSV Health Investors joins Xilio Therapeutics’ $100.5 million Series B financing - proceeds will advance XTX201 and XTX101 into the clinic while expanding Xilio’s cytokine pipeline
- 3 March 2020Portfolio NewsAmwell Launches National COVID-19 Telehealth Response Program
- 2 March 2020Portfolio NewsEvelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
- 2 March 2020Portfolio NewsAkrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
- 27 February 2020Portfolio NewsSutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
- 25 February 2020Portfolio NewsBicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies
- 19 February 2020Portfolio NewsDeciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
- 18 February 2020Portfolio NewsEndotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial
- 10 February 2020Portfolio NewsAVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and plato™ Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
- 10 February 2020Portfolio NewsArtios Pharma Strengthens Clinical Development Team with Senior Appointments